RxDoctor Payments Data

Jeffery Auletta

Pediatric Hematology-Oncology · Columbus, OHNPI 1649298365

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,750 of the $7,885 with a category attached, or 98.3%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $5,250 and has fallen 99.7% since, to $17 in 2025.

$7,885in general payments, 2019–2025

Across 6 payments — averaging $1314.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$8K
  • AbbVie$118
  • Medexus Pharma, Inc.$17
$700,000in research payments, 2019–2025

Across 4 payments — averaging $175,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$600K
  • Incyte Corporation$100K

What the payments were for

  • Consulting fees$7,75098%
  • Food & beverage$170%
  • Education$1181%

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,885 in reported general payments places this provider in the 65th percentile of 143 pediatric hematology-oncology providers in Ohio.

See all pediatric hematology-oncology providers in Ohio

Other pediatric hematology-oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →